Columbia, MD – (August 11, 2014) – ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced expansion of its Columbia, Maryland headquarters to increase manufacturing, research and development capacity.
The expansion will increase Research and Development space from 1,000 to 3,000 square feet of academic style laboratories equipped to support state-of-the-art clean room research, product development and pilot scale production endeavors.
“The new lab spaces will enable ACell to further explore how our technology can be leveraged to help more patients through the development of new products for a wide range of clinical applications,” said Thomas Gilbert, Ph.D., Vice President, Research and Development.
The renovation also includes an 8,000 square foot expansion of a fully integrated manufacturing facility that will augment and support the existing manufacturing facility in Lafayette, Indiana. “By adding additional end-to-end manufacturing capabilities, ACell has increased capacity to meet rapidly growing demand as well as establishing redundancy in manufacturing capabilities and ensuring continuity of production,” said Bob Naugler, Vice President Operations.
ACell has averaged a 30% annual growth rate since 2012. “We are proud of how quickly the use of MatriStem medical devices is growing,” said ACell President and COO, Rodney Bosley. “By reinvesting in research, product development and manufacturing through projects like this, we continue to position ACell as an innovator and leader in regenerative medicine.”
ACell offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products that facilitate repair and remodeling of damaged tissues by the patient in a broad range of applications. Its patented MatriStem ECM medical devices are available in particle and sheet forms for the management and reinforcement of wounds and various surgical procedures. For more information, visit www.acell.com.
About ACell, Inc.
ACell, Inc. is a leading company in the field of regenerative medicine, focused on the development, manufacturing and commercialization of tissue repair products. Its medical devices are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held company, ACell produces MatriStem at its full scale manufacturing facility in Lafayette, IN, and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem products are porcine-derived extracellular matrix (ECM) scaffolds that contain the epithelial basement membrane from porcine urinary bladder tissue, or urinary bladder matrix (UBM). UBM is a layer of tissue that facilitates a constructive tissue remodeling response by the patient’s body. It provides MatriStem products with several distinguishable characteristics, including the ability to be resorbed by the patient as it is replaced by site appropriate tissue following implantation; the ability to be used “off-the-shelf” and stored at room temperature, with up to a two year shelf life; and superior ease-of-use characteristics. MatriStem products are indicated for use in a wide range of tissue repair applications and come in a range of sizes and thicknesses. They have been cleared for use in general surgery, gynecological surgery and a wide range of wounds, including diabetic foot ulcers (DFU), venous leg ulcers (VLU), pressure, surgical, and tunneled wounds. Refer to the IFU supplied with each device for indications, contraindications and precautions. All MatriStem devices are made in the USA.Return to News